NCT01468233.

Trial name or title	A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa ‐ PIONEER II
Methods	This is a phase 3 parallel RCT
Participants	The trial is including adults with moderate to severe HS
Interventions	Adalimumab every week/adalimumab alternate weeks/placebo
Outcomes	Improvement in "HS severity"
Starting date	November 2011 (likely finish May 2014)
Contact information	Martin Okun MD Study Chair, Abbott Andrea L Byars (andrea.byars@abbott.com)
Notes	AbbVie sponsor the trial (prior sponsor: Abbott)